Endocrinology, Vol 136, 1898-1906, Copyright © 1995 by Endocrine Society

ARTICLES

Androgen ablation-induced programmed death of prostatic glandular cells does not involve recruitment into a defective cell cycle or p53 induction

Y Furuya, XS Lin, JC Walsh, WG Nelson and JT Isaacs
Johns Hopkins Oncology Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.

Proliferating cells characteristically undergo programmed (i.e. apoptotic) death if their progression through the cell cycle is sufficiently perturbed. To determine whether androgen ablation-induced programmed death of prostatic glandular cells involves apoptosis triggered by recruitment of nonproliferating cells into a perturbed cell cycle, rat ventral prostates were assessed temporally after castration for several stereotypical molecular stigmata of entry into the proliferative cell cycle. Northern blot analysis was used to assess levels of transcripts from genes characteristically activated 1) during the transition from quiescence (G(0)) into G1 of the proliferative cell cycle (cyclin-D1 and cyclin-C), 2) during the transition from G1 to S (cyclin-E, cdk2, thymidine kinase, and H4-histone), and 3) during progression through S (cyclin-A). Although levels of each of these transcripts increased as expected in prostatic glandular epithelial cells stimulated to proliferate by the administration of exogenous androgen to previously castrated rats, levels of the same transcripts decreased in prostatic glandular cells induced to undergo apoptosis after androgen withdrawal. Northern and Western blot analyses also demonstrated that there was no increase in prostatic p53 messenger RNA or protein content per cell after androgen ablation. Likewise, after castration, there was no enhanced prostatic expression of the WAF1/CIP1 gene, a gene whose expression is known to be induced in both a p53- dependent and -independent manner during recruitment from G0 into G1. In addition, androgen ablation-induced apoptosis of prostatic glandular cells was not accompanied by retinoblastoma protein phosphorylation, which is characteristic of progression into late G1. Nuclear run-on assays demonstrated that there was no increase in the prostatic rate of transcription of the c-myc and c-fos genes after castration. These results demonstrate that prostatic glandular cells undergo programmed death in G(0) without recruitment into the G1 phase of a defective cell cycle, and that an increase in p53 protein or its function is not involved in this death process.

This article has been cited by other articles:

				F. Jiang and Z. Wang Identification of Androgen-Responsive Genes in the Rat Ventral Prostate by Complementary Deoxyribonucleic Acid Subtraction and Microarray Endocrinology, April 1, 2003; 144(4): 1257 - 1265. [Abstract] [Full Text] [PDF]

				M. Jara, P. Esponda, and R. Carballada Abdominal Temperature Induces Region-Specific p53-Independent Apoptosis in the Cauda Epididymidis of the Mouse Biol Reprod, October 1, 2002; 67(4): 1189 - 1196. [Abstract] [Full Text] [PDF]

				P. Hilgard, T. Huang, A. W. Wolkoff, and R. J. Stockert Translated Alu sequence determines nuclear localization of a novel catalytic subunit of casein kinase 2 Am J Physiol Cell Physiol, August 1, 2002; 283(2): C472 - C483. [Abstract] [Full Text] [PDF]

				A. A. Goyeneche, V. Calvo, G. Gibori, and C. M. Telleria Androstenedione Interferes in Luteal Regression by Inhibiting Apoptosis and Stimulating Progesterone Production Biol Reprod, May 1, 2002; 66(5): 1540 - 1547. [Abstract] [Full Text]

				D. Waltregny, I. Leav, S. Signoretti, P. Soung, D. Lin, F. Merk, J. Y. Adams, N. Bhattacharya, N. Cirenei, and M. Loda Androgen-Driven Prostate Epithelial Cell Proliferation and Differentiation in Vivo Involve the Regulation of p27 Mol. Endocrinol., May 1, 2001; 15(5): 765 - 782. [Abstract] [Full Text]

				Y. M. Shuba, N. Prevarskaya, L. Lemonnier, F. Van Coppenolle, P. G. Kostyuk, B. Mauroy, and R. Skryma Volume-regulated chloride conductance in the LNCaP human prostate cancer cell line Am J Physiol Cell Physiol, October 1, 2000; 279(4): C1144 - C1154. [Abstract] [Full Text] [PDF]

				R. G. Pestell, C. Albanese, A. T. Reutens, J. E. Segall, R. J. Lee, and A. Arnold The Cyclins and Cyclin-Dependent Kinase Inhibitors in Hormonal Regulation of Proliferation and Differentiation Endocr. Rev., August 1, 1999; 20(4): 501 - 534. [Abstract] [Full Text] [PDF]

				R.-s. Ge and M. P. Hardy Decreased Cyclin A2 and Increased Cyclin G1 Levels Coincide with Loss of Proliferative Capacity in Rat Leydig Cells During Pubertal Development Endocrinology, September 1, 1997; 138(9): 3719 - 3726. [Abstract] [Full Text] [PDF]

				M. L. Day, R. G. Foster, K. C. Day, X. Zhao, P. Humphrey, P. Swanson, A. A. Postigo, S. H. Zhang, and D. C. Dean Cell Anchorage Regulates Apoptosis through the Retinoblastoma Tumor Suppressor/E2F Pathway J. Biol. Chem., March 28, 1997; 272(13): 8125 - 8128. [Abstract] [Full Text] [PDF]

				C. Guo, S. Yu, A. T. Davis, H. Wang, J. E. Green, and K. Ahmed A Potential Role of Nuclear Matrix-associated Protein Kinase CK2 in Protection against Drug-induced Apoptosis in Cancer Cells J. Biol. Chem., February 16, 2001; 276(8): 5992 - 5999. [Abstract] [Full Text] [PDF]